Autism spectrum disorder (ASD) is a characteristically heterogeneous disorder, as multiple neurodevelopmental disorders are characterized by similar symptomology and behavior. Research has shown that individuals with ASD benefit from early intervention; neuroimaging data may reveal information that cannot be obtained from traditional behavioral analysis. This review discusses the use of structural MR imaging, functional MR imaging (fMR imaging), and PET in the detection of ASD. Larger datasets, standardized methods of collection and analysis, and more robust meta-analyses are required to implement the observed biomarkers and improve the lives of patients living with AUD.

Degenerative disc disease (DDD) is a common spinal condition characterized by the deterioration of intervertebral discs, leading to chronic back pain and reduced mobility. While magnetic resonance imaging (MRI) has long been the standard for late-stage DDD diagnosis, its limitations in early-stage detection prompt the exploration of advanced imaging methods. Positron emission tomography/computed tomography (PET/CT) using 18F- fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF) has shown promise in identifying metabolic imbalances and age-related spinal degeneration, thereby complementing CT grading of the disease. The novel hybrid imaging modality PET/MRI provides new opportunities and are briefly discussed. The complex pathophysiology of DDD is dissected to highlight the role of genetic predisposition and lifestyle factors such as smoking and obesity. These etiological factors significantly impact the lumbosacral region, manifesting in chronic low back pain (LBP) and potential nerve compression. Traditional grading systems, like the Pfirrmann classification for MRI, are evaluated for their limitations in capturing the full spectrum of DDD. The potential to identify early disease processes and predict patient outcomes by the use of artificial intelligence (AI) is also briefly mentioned. Overall, the manuscript aims to spotlight advancements in imaging technologies for DDD, emphasizing their implications in refining both diagnosis and treatment strategies. The role of ongoing and future research is emphasized to validate these emerging techniques and overcome current limitations for more effective early detection and treatment.

VaD is a significant cause of cognitive deterioration that is strongly associated with modifiable cardiovascular and atherosclerotic risk factors. PET imaging provides a novel avenue to visualize early-stage pathogenesis, characterized by potentially reversible neuronal and vascular changes that precede the onset of irreversible structural alterations and cognitive dysfunction. FDG PET captures patterns of metabolic activity in the brain that can aid in the identification of VaD and its subtypes, whereas NaF PET may capture subclinical atherosclerosis in the major arterial beds supplying the brain. Though PET faces several limitations, such as accessibility, implementation, and radiation exposure, we believe that the multi- modal integration of PET imaging will permit a comprehensive understanding of VaD pathophysiology and play a leading role in the future study of therapeutics.

PET imaging has been instrumental in investigating and evaluating the complete disease process of AD. Recent innovations in tracer development, artificial intelligence techniques, and -omics models have further elevated the value of PET inAD.114Expanding on this role, PET techniques are likely to remain crucial in uncovering AD's path-ophysiology, managing the disease clinically, and designing and assessing therapeutic strategies targeting AD pathology.

Carotid artery atherosclerosis, a significant manifestation of cardiovascular disease (CVD) and leading cause of stroke, develops through a gradual process of arterial inflammation and calcification. This study explores the relationship between arterial inflammation (18 F-FDG PET/CT) and vascular calcification (18 F-NaF PET/CT) in the left and right common carotid arteries (LCC/RCC) and their association with CVD and thromboembolic risk in patients with subclinical atherosclerosis. A cohort of 115 subjects (73 healthy volunteers, 42 at-risk for CVD) underwent 18 F-NaF and 18 F-FDG PET/CT imaging. Radiotracer uptake was quantitatively assessed by measuring the average blood-pool-corrected mean standardized uptake value (aSUVmean). Relative to healthy volunteers, at-risk subjects had greater uptake of NaF and FDG (10–22 https://clinicaltrials.gov/study/NCT01724749 .

Traumatic brain injury (TBI) is a major health concern in the United States and worldwide. Neuroimaging is a critical element in the clinical evaluation of TBIs, as computed tomography (CT) and MR imaging are commonly used to identify structural changes that may aid in treatment decision-making and long-term patient monitoring. This article reviews the utility of CT and MR imaging while focusing on the emerging applications of PET in TBI. Pertinent research findings in the molecular imaging of cerebral metabolism, tau and β-amyloid, neurotransmitters, and neuroinflammation are discussed.

Pediatric Langerhans Cell Histiocytosis (LCH) is a rare disorder characterized by the clonal proliferation of Langerhans cells, leading to the formation of granulomatous lesions. While the disease can affect various organs, skin involvement is a prominent feature and serves as a diagnostic indicator. In recent years, non-invasive imaging techniques have been used to in the diagnosis and management of this condition. Specifically, there is diagnostic significance for the use of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in cases where skin symptoms of LCH mimic other dermatological conditions or malignancies. FDG-PET enables the visualization of glucose metabolism within skin lesions, aiding in the differentiation between active and inactive disease sites. A systematic review was conducted to summarize the utility of nuclear imaging techniques in pediatric LCH. PubMed, Scopus, and ScienceDirect databases were utilized for relevant articles. A total of 276 citations were identified in the initial search. Following the review of titles, abstracts, and duplicates, 269 articles were excluded, leaving a total of 7 articles for analysis. Data were extracted from each article, encompassing the number of patients, imaging techniques employed, and final results. Analysis highlights the effectiveness of FDG-PET in assessing disease extent, guiding biopsy site selection, and monitoring treatment response. The sensitivity of FDG-PET to identify hidden bone involvement in the vicinity of cutaneous lesions enhances disease staging and guides treatment decisions. Studies have suggested that FDG-PET can serve as a prognostic tool, predicting the clinical course of the disease and aiding in the tailoring of therapeutic interventions.

Langerhans cell histiocytosis (LCH) is a complex disorder characterized by the clonal proliferation of Langerhans cells, primarily affecting children and adolescents. This condition exhibits a wide spectrum of clinical presentations, necessitating a multidisciplinary approach for diagnosis, treatment, and follow-up. Cutaneous manifestations of LCH are significant, mimicking common dermatoses and posing diagnostic challenges. [18F]Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) has emerged as an important tool in the evaluation of pediatric LCH, offering insights into disease activity, extent, and therapeutic response. Moreover, FDG-PET provides a non-invasive means to distinguish between active LCH skin lesions and other dermatological conditions with similar clinical appearances, enhancing diagnostic accuracy and aiding in disease monitoring. This educational review summarizes the utility of nuclear imaging techniques, with a focus on PET scans, in the diagnosis and management of cutaneous pediatric LCH. A comprehensive literature search identified seven relevant articles, including retrospective studies and case reports. These studies highlight the efficacy of FDG-PET in localizing active LCH skin lesions, monitoring disease activity, and guiding treatment decisions. FDG-PET represents a valuable imaging modality for dermatologists, oncologists, and pediatricians managing pediatric LCH patients with cutaneous involvement. This non-invasive technique contributes to improved diagnostic accuracy and facilitates early intervention, ultimately enhancing patient care and outcomes.

Purpose Statins are widely recognized for their efficacy in reducing cardiovascular risk through cholesterol reduction. Their use, however, is occasionally associated with adverse muscular effects, ranging from mild myalgias to statin-induced necrotizing autoimmune myopathies (SINAM). SINAM presents a significant clinical challenge due to persistent muscle weakness and elevated creatine kinase (CK) levels, even after statin withdrawal. Methods We explored the diagnostic journey of a 69-year-old African-American male with a history of extensive statin use, who presented with progressive muscular weakness and exceptionally high CK levels. A multidisciplinary diagnostic approach was employed, involving comprehensive laboratory testing, electromyography, muscle biopsy, and advanced imaging techniques. The diagnosis of SINAM was confirmed by identifying anti-HMGCR antibodies. Results Despite cessation of statin therapy, the patient's muscular symptoms persisted, with laboratory tests revealing remarkably elevated CK levels. The initiation of immunosuppressive therapy, including corticosteroids and intravenous immunoglobulin, led to a gradual improvement in muscle strength and a decrease in CK levels. However, the recovery journey highlighted the chronic nature of SINAM, necessitating ongoing management and careful consideration of long-term immunosuppressive treatment strategies. Conclusion This case report emphasizes the critical need for heightened vigilance and a high index of suspicion among healthcare providers when patients present with unexplained muscle weakness and elevated CK levels following statin use. Early and accurate diagnosis of SINAM, followed by the prompt initiation of immunosuppressive therapy, is paramount in preventing irreversible muscle damage and optimizing patient outcomes. Future research should focus on elucidating the precise mechanisms underlying SINAM, identifying at-risk populations, and developing targeted treatment protocols.

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS) affect millions and present significant challenges in healthcare and treatment costs. The debate in the field pivots around two hypotheses: synaptic spread and selective vulnerability. Pioneers like Virginia Lee and John Trojanowski have been instrumental in identifying key proteins (tau, alpha-synuclein, TDP-43) central to these diseases. The synaptic spread hypothesis suggests a cell-to-cell propagation of pathogenic proteins across neuronal synapses, influencing disease progression, with studies highlighting the role of proteins like alpha-synuclein and amyloid-beta in this process. In contrast, the selective vulnerability hypothesis proposes inherent susceptibility of certain neurons to degeneration due to factors like metabolic stress, leading to protein aggregation. Recent advancements in neuroimaging, especially PET/MRI hybrid imaging, offer new insights into these mechanisms. While both hypotheses offer substantial evidence, their relative contributions to neurodegenerative processes remain to be fully elucidated. This uncertainty underscores the necessity for continued research, with a focus on these hypotheses, to develop effective treatments for these devastating diseases.

BACKGROUND:Despite their asymptomatic occurrence, unruptured intracranial aneurysms (UIAs) account for a significant proportion of hospital charges and healthcare resource utilization in the United States. Hospital length of stay (LOS) is a reimbursement metric utilized to incentivize value-based care. Our study identifies predictors of extended LOS (eLOS) after elective treatment of UIAs. METHODS:This was a retrospective study of 525 patients who underwent elective treatment of an UIA at a single institution. Data were collected with regard to demographics, clinical presentation, treatment characteristics, and postoperative outcomes. The primary outcome, eLOS, was defined as hospital stay in the upper quartile of the median (≥75th percentile). Univariate and multivariate analyses were performed to identify factors predictive of eLOS in this cohort. RESULTS:The average age of the cohort was 61.40, standard deviation=11.41. 77.3% of the cohort was female. The median duration of LOS was 2 days (interquartile range: 1-5). 11.6% experienced eLOS (≥5 days). Multivariate logistic regression identified age (OR: 1.04, 95% confidence interval [CI]: 1.01-1.07), coexistent vascular pathology (OR: 21.33, 95% CI: 8.06-56.39), open surgery (OR: 3.93, 95% CI: 1.85-8.34), and postoperative stroke (OR: 11.72, 95% CI: 3.18-43.18) as independent predictors of eLOS. CONCLUSIONS:Our study identified predictors of eLOS that could help promote risk stratification prior to treatment of UIAs. Future research that identifies predictors of long-term outcomes based on treatment modality could help identify ways to improve healthcare resource utilization in this cohort.

Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft-versus-host disease. Since then, topical and oral formulations have gained FDA approval for pediatric patients with dermatologic diseases. While increasing evidence supports the safety of these medications in adults, data are limited in children. We sought to determine whether JAKi adverse events (AEs) as reported in clinical trials and via postapproval pharmacovigilance services are comparable in adult and pediatric patients. Pharmacovigilance data were extracted from the FDA's Adverse Event Reporting System and the Canada Vigilance Adverse Reaction Online Database for baricitinib, upadacitinib, abrocitinib, ruxolitinib, and tofacitinib. The pooled data were analyzed to detect the most common AEs for specific JAKi and for the drug class. We assessed 399,649 AEs from 133,216 adults and 2883 AEs from 955 patients under 18 years old and identified slightly different AE profiles for the two age groups. Both populations had increased risk for infections and gastrointestinal AEs. However, pediatric patients reported a higher proportion of blood and lymphatic disorders, while reports of nervous system and musculoskeletal/connective tissue disorders were more common in adults. The spectrum of AEs extracted from pharmacovigilance reports was similar to clinical trials. The JAKi AE profiles we observed may prove helpful in counseling patients and their parents before starting therapy and for monitoring once patients are on therapy.

Primary progressive aphasia (PPA) is a disease known to affect the frontal and temporal regions of the left hemisphere. PPA is often an indication of future development of dementia, specifically semantic dementia (SD) for frontotemporal dementia (FTD) and logopenic progressive aphasia (LPA) as an atypical presentation of Alzheimer’s disease (AD). The purpose of this review is to clarify the value of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) in the detection and diagnosis of PPA. A comprehensive review of literature was conducted using Web of Science, PubMed, and Google Scholar. The three PPA subtypes show distinct regions of hypometabolism in FDG-PET imaging with SD in the anterior temporal lobes, LPA in the left temporo-parietal junction, and nonfluent/agrammatic Variant PPA (nfvPPA) in the left inferior frontal gyrus and insula. Despite the distinct patterns, overlapping hypometabolic areas can complicate differential diagnosis, especially in patients with SD who are frequently diagnosed with AD. Integration with other diagnostic tools could refine the diagnostic process and lead to improved patient outcomes. Future research should focus on validating these findings in larger populations and exploring the therapeutic implications of early, accurate PPA diagnosis with more targeted therapeutic interventions.

OBJECTIVE: Few studies have reported the impact of telescoping flow diverters (FDs) in intracranial aneurysm telescoping FDs to those treated with a single FD and identified predictors of telescoping. METHODS: This was a single-center retrospective review of a prospectively maintained database of aneurysms treated with FDs between 2011 and 2023. All patients who were treated with FDs for intracranial aneurysms were included in the study. RESULTS: The study comprised 750 patients with 750 aneurysms treated using 871 FDs. The study cohort was divided into 85 patients requiring telescoping FDs and 655 who did not. Rates of hemorrhage (7.1% vs. 1.8%, P< 0.001), symptomatic stroke (5.9% vs. 2.6, P < 0.001), and asymphigher in the telescoping cohorts. At final follow-up, the rate of nonocclusion (9.8% vs. 5.1%, P = 0.029) and the rate of complete occlusion (88.5% vs. 81.1%, P = 0.029) were significantly higher in the telescoping cohort. On multianeurysm height (OR: 1.0, 95% CI 1.0-1.1, P= 0.034), and the use of the Pipeline Embolization Device FD (OR: 2.4, 95% CI 1.3-4.4, P = 0.005) were independent predictors of telescoping. CONCLUSIONS: Aneurysms with fusiform morphology, increasing aneurysm height and those that underwent flow diversion using Pipeline Embolization Device had higher odds for telescoping. Significantly higher rates of angiographic occlusion with the use of telescoping FD add to the literature on its efficacy in treating aneurysms of varying morphology.